NCT02953301

Resminostat for Maintenance Treatment of Patients With Advanced Stage Mycosis Fungoides (MF) or Sézary Syndrome (SS)

A Multicentre, Double Blind, Randomised, Placebo-controlled, Phase II Trial to Evaluate Resminostat for Maintenance Treatment of Patients With Advanced Stage (Stage IIB-IVB) Mycosis Fungoides (MF) or Sézary Syndrome (SS) That Have Achieved Disease Control With Systemic Therapy - the RESMAIN Study

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 201 (actual)
• Sponsor: 4SC AG · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to determine whether resminostat will be able to delay or prevent worsening of disease in patients with advanced stage mycosis fungoides or Sézary Syndrome that have recently achieved disease control with previous systemic therapy.

Conditions

• Mycosis Fungoides
• Sezary Syndrome
• Lymphoma, T-Cell, Cutaneous

Interventions

Type	Name	Description
DRUG	resminostat
DRUG	Placebo

Timeline

• Start date: 2016-11-01
• Primary completion: 2023-03-01
• Completion: 2024-08-01
• First posted: 2016-11-02
• Last updated: 2024-08-30

Locations

54 sites across 12 countries: Austria, Belgium, France, Germany, Greece, Italy, Japan, Netherlands, Poland, Spain, Switzerland, United Kingdom